Evidence map›Paper›PMID 39813006›Full record

ArticleJournal of cardiovascular translational research2025

Chitinase-3-like Protein 1 Reduces the Stability of Atherosclerotic Plaque via Impairing Macrophagic Efferocytosis.

Yandong Liu, Weilin Hu, Futang Yang, Sili Zou, Huiqiong Ren, Yong Zuo, Lefeng Qu

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yandong Liu *Department of Geriatrics, 905, Hospital of PLA NAVY, Shanghai, China.
Weilin Hu *Department of Vascular and Endovascular Surgery, Changzheng Hospital, Affiliated to the Naval Medical University, Shanghai, 200003, China.
Futang Yang *Department of Vascular and Endovascular Surgery, Changzheng Hospital, Affiliated to the Naval Medical University, Shanghai, 200003, China.
Sili ZouDepartment of Vascular and Endovascular Surgery, Changzheng Hospital, Affiliated to the Naval Medical University, Shanghai, 200003, China.
Huiqiong RenDepartment of Geriatrics, 905, Hospital of PLA NAVY, Shanghai, China. shjfj85yy@163.com.
Yong ZuoDepartment of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zuoyong@shsmu.edu.cn.
Lefeng QuDepartment of Vascular and Endovascular Surgery, Changzheng Hospital, Affiliated to the Naval Medical University, Shanghai, 200003, China. qulefeng@163.com.ORCID 0009-0001-6145-0043

Funding

National Natural Science Foundation of China 82200540Science and Technology Commission of Shanghai Municipality 22YF1458400Shanghai Changning District Health Committee Youth Project 2023QN24
6 · The paper itself

Abstract

CHI3L1 is strongly associated with atherosclerosis, but its role in macrophages remains unknown. In this study, we observed a significant up-regulation of CHI3L1 in both carotid plaques and serum of symptomatic patients, and demonstrated that CHI3L1 impairs the efferocytosis of macrophages by down-regulating crucial efferocytic mediator MFGE8 through inhibiting ATF2, which binds directly to the enhancer of MFGE8. In human plaques, we observed a negative correlation between CHI3L1 expression and both ATF2 and MFGE8 levels, further proved their involvement in plaque destabilization. Using Ldlr-/- mice with tandem carotid stenosis surgery, we demonstrated that administration of CHI3L1 protein resulted in enlarged atherosclerotic necrotic cores and decreased MFGE8 and ATF2 levels. Conversely, treatment with a CHI3L1 blocking antibody exhibited the opposite trend.In conclusion, CHI3L1 destabilizes atherosclerotic plaque by impairing macrophagic efferocytosis through the down-regulation of ATF2-induced MFGE8 expression. Targeting CHI3L1 may offer a promising therapeutic strategy for the treatment of atherosclerosis.

Indexed as

Carotid ArteriesCarotid Artery DiseasesCarotid StenosisChitinase-3-Like Protein 1MacrophagesPhagocytosisPlaque, AtheroscleroticActivating Transcription Factor 2AgedAnimalsDisease Models, AnimalEfferocytosisFemaleHumansMaleMiceActivating Transcription Factor 2CHI3L1 protein, humanChil1 protein, mouseChitinase-3-Like Protein 1Receptors, LDLAtherosclerosisChitinase-3-like protein 1EfferocytosisMacrophagesPlaque vulnerabilityStroke

Identifiers

PMID39813006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.